NCT06162143View on ClinicalTrials.gov

Effect of Gelsectan® in the Treatment of Low Anterior Resection Syndrome

RecruitingOBSERVATIONAL
Enrollment

73

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

June 15, 2025

Study Completion Date

November 15, 2025

Conditions
Low Anterior Resection Syndrome
Interventions
DEVICE

Gelsectan®

Gelsectan® is a CE-marked class II device containing xyloglucans, xylo-oligosaccharides, pea proteins, and tannins from grape seeds extract, already used in Irritable Bowel Syndrome (IBS).

Trial Locations (1)

20089

RECRUITING

IRCCS Humanitas Research Hospital, Rozzano

All Listed Sponsors
lead

Istituto Clinico Humanitas

OTHER